JP7513605B2 - 新規な抗体ならびにそれを調製および使用するための方法 - Google Patents

新規な抗体ならびにそれを調製および使用するための方法 Download PDF

Info

Publication number
JP7513605B2
JP7513605B2 JP2021526401A JP2021526401A JP7513605B2 JP 7513605 B2 JP7513605 B2 JP 7513605B2 JP 2021526401 A JP2021526401 A JP 2021526401A JP 2021526401 A JP2021526401 A JP 2021526401A JP 7513605 B2 JP7513605 B2 JP 7513605B2
Authority
JP
Japan
Prior art keywords
antibody
amino acid
seq
acid sequence
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021526401A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021530251A (ja
JPWO2020018852A5 (https=
JP2021530251A5 (https=
Inventor
ル，ユエフォン
ル，ジェン－フォン
シャネベック，カート
リ，ルー
リュウ，レイ
チョウ，シーウェン
ラン，ヤン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Askgene Pharma Inc
Original Assignee
Askgene Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Askgene Pharma Inc filed Critical Askgene Pharma Inc
Publication of JP2021530251A publication Critical patent/JP2021530251A/ja
Publication of JPWO2020018852A5 publication Critical patent/JPWO2020018852A5/ja
Publication of JP2021530251A5 publication Critical patent/JP2021530251A5/ja
Priority to JP2024103530A priority Critical patent/JP2024133536A/ja
Application granted granted Critical
Publication of JP7513605B2 publication Critical patent/JP7513605B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2021526401A 2018-07-18 2019-07-18 新規な抗体ならびにそれを調製および使用するための方法 Active JP7513605B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024103530A JP2024133536A (ja) 2018-07-18 2024-06-27 新規な抗体ならびにそれを調製および使用するための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862700174P 2018-07-18 2018-07-18
US62/700,174 2018-07-18
US201962792798P 2019-01-15 2019-01-15
US62/792,798 2019-01-15
PCT/US2019/042493 WO2020018852A2 (en) 2018-07-18 2019-07-18 Novel antibodies and methods for making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024103530A Division JP2024133536A (ja) 2018-07-18 2024-06-27 新規な抗体ならびにそれを調製および使用するための方法

Publications (4)

Publication Number Publication Date
JP2021530251A JP2021530251A (ja) 2021-11-11
JPWO2020018852A5 JPWO2020018852A5 (https=) 2023-03-10
JP2021530251A5 JP2021530251A5 (https=) 2023-03-10
JP7513605B2 true JP7513605B2 (ja) 2024-07-09

Family

ID=69165232

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021526401A Active JP7513605B2 (ja) 2018-07-18 2019-07-18 新規な抗体ならびにそれを調製および使用するための方法
JP2024103530A Pending JP2024133536A (ja) 2018-07-18 2024-06-27 新規な抗体ならびにそれを調製および使用するための方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024103530A Pending JP2024133536A (ja) 2018-07-18 2024-06-27 新規な抗体ならびにそれを調製および使用するための方法

Country Status (5)

Country Link
US (2) US11505618B2 (https=)
EP (1) EP3824096A4 (https=)
JP (2) JP7513605B2 (https=)
CN (1) CN112513093B (https=)
WO (1) WO2020018852A2 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11505618B2 (en) * 2018-07-18 2022-11-22 Askgene Pharma Inc. Antibodies and methods for making and using the same
CA3128502A1 (en) 2019-02-01 2020-08-06 Novarock Biotherapeutics, Ltd. Anti-claudin 18 antibodies and methods of use thereof
WO2021160154A1 (zh) * 2020-02-10 2021-08-19 上海诗健生物科技有限公司 Cldn18.2抗体及其用途
IL298184A (en) * 2020-05-15 2023-01-01 Sichuan Kelun Biotech Biopharmaceutical Co Ltd Antibody drug conjugate, preparation method therefor and use thereof
WO2022012559A1 (zh) * 2020-07-13 2022-01-20 上海君实生物医药科技股份有限公司 抗cldn-18.2抗体及其用途
CN113929780A (zh) * 2020-07-13 2022-01-14 北京凯因科技股份有限公司 一种结合密蛋白的用于治疗癌症的人源化抗体
CN111704669B (zh) * 2020-07-13 2022-05-13 北京凯因科技股份有限公司 一种用于治疗晚期胃癌的抗cldn18全人源化抗体
US20240034784A1 (en) * 2020-09-30 2024-02-01 Nanjing GenScript Biotech Co., Ltd. Antibodies targeting human claudin 18.2 and uses thereof
CN114504642B (zh) * 2020-11-17 2026-03-27 江苏奥赛康生物医药有限公司 一种含抗cldn18.2抗体的液体药物组合物
WO2022122709A1 (en) 2020-12-07 2022-06-16 Sotio Biotech A.S. Antibody-drug conjugates based on humanized cldn18.2 antibodies
CA3199830A1 (en) 2020-12-23 2022-06-30 Lukas BAMMERT Tumor-specific claudin 18.2 antibody-drug conjugates
CN114805571B (zh) * 2021-01-28 2023-08-25 广西鹭港生物医药科技有限公司 抗cldn18.2抗体及其应用
EP4299593A4 (en) * 2021-04-02 2025-12-10 Oricell Therapeutics Co Ltd CLDN18.2 ANTIGEN-BINDING PROTEIN AND ITS USE
CN115611983A (zh) * 2021-07-14 2023-01-17 三优生物医药(上海)有限公司 Cldn18.2结合分子及其用途
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
KR20250129814A (ko) 2023-01-18 2025-08-29 타이리간드 바이오사이언스 (상하이) 리미티드 항체-약물 접합체 및 이의 용도
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof
EP4716702A2 (en) * 2023-05-22 2026-04-01 SystImmune, Inc. Anti-claudin18.2 antibody and method of making and using thereof
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025082356A1 (zh) * 2023-10-16 2025-04-24 江苏奥赛康生物医药有限公司 Cldn18_2抗体与化学治疗药物的组合及其应用
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2026050213A1 (en) 2024-08-27 2026-03-05 Usbolt Biotherapeutics, Inc. Tlr agonist immunoconjugates and uses thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517354A (ja) 2005-11-24 2009-04-30 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
US20150157711A1 (en) 2012-05-23 2015-06-11 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2015517476A (ja) 2012-05-09 2015-06-22 ガニメド ファーマシューティカルズ アーゲー 癌診断に有用なクローディン１８．２に対する抗体
US20150374789A1 (en) 2013-02-20 2015-12-31 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2016517447A (ja) 2013-03-18 2016-06-16 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む治療法
US20180055944A1 (en) 2016-08-01 2018-03-01 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
JP2018513146A (ja) 2015-04-15 2018-05-24 ガニメド ファーマシューティカルズ ゲーエムベーハー クローディン１８．２に対する抗体を含む薬物コンジュゲート
JP2019535234A (ja) 2016-09-23 2019-12-12 バイオンテック アーゲー クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019173832A2 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
US11505618B2 (en) * 2018-07-18 2022-11-22 Askgene Pharma Inc. Antibodies and methods for making and using the same

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009517354A (ja) 2005-11-24 2009-04-30 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８に対するモノクローナル抗体
JP2015517476A (ja) 2012-05-09 2015-06-22 ガニメド ファーマシューティカルズ アーゲー 癌診断に有用なクローディン１８．２に対する抗体
US20150157711A1 (en) 2012-05-23 2015-06-11 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
US20150374789A1 (en) 2013-02-20 2015-12-31 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
JP2016517447A (ja) 2013-03-18 2016-06-16 ガニメド ファーマシューティカルズ アーゲー 癌の治療のためのクローディン１８．２に対する抗体を含む治療法
JP2018513146A (ja) 2015-04-15 2018-05-24 ガニメド ファーマシューティカルズ ゲーエムベーハー クローディン１８．２に対する抗体を含む薬物コンジュゲート
US20180055944A1 (en) 2016-08-01 2018-03-01 Askgene Pharma Inc. Novel antibody-albumin-drug conjugates (aadc) and methods for using them
JP2019535234A (ja) 2016-09-23 2019-12-12 バイオンテック アーゲー クローディン発現がん疾患の処置のためのクローディン６又はクローディン１８．２とｃｄ３とに結合する二重特異的三価抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cancer Research，2011年，Vol.71, No.2，pp.516-527，https://aacrjournals.org/cancerres/article/71/2/516/568756/Highly-Specific-Auto-Antibodies-against-Claudin-18参照

Also Published As

Publication number Publication date
JP2021530251A (ja) 2021-11-11
WO2020018852A2 (en) 2020-01-23
JP2024133536A (ja) 2024-10-02
US11505618B2 (en) 2022-11-22
US20230303714A1 (en) 2023-09-28
EP3824096A4 (en) 2022-04-20
CN112513093A (zh) 2021-03-16
US12312413B2 (en) 2025-05-27
US20200040101A1 (en) 2020-02-06
EP3824096A2 (en) 2021-05-26
CN112513093B (zh) 2024-08-09

Similar Documents

Publication Publication Date Title
JP7513605B2 (ja) 新規な抗体ならびにそれを調製および使用するための方法
JP7520848B2 (ja) 癌および他の疾患の治療のための、クローディン１８．２に特異的な結合分子、その組成物および方法
TWI708788B (zh) 雙特異性抗體
JP7801095B2 (ja) 二重特異性抗体およびその使用
US20190106494A1 (en) PD-L1 Specific Monoclonal Antibodies for Disease Treatment and Diagnosis
CN115698072B (zh) 抗gpc3抗体，抗gpc3嵌合抗原受体和gpc3/cd3双特异性抗体
CA3087105A1 (en) Pd-l1 antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
US20240109963A1 (en) Multispecific antibodies and uses thereof
BR112020014848A2 (pt) Anticorpo anti-4-1bb, fragmento de ligação ao antígeno do mesmo e uso médico do mesmo
US20240002539A1 (en) Multispecific antibodies and uses thereof
KR20250060324A (ko) 이중특이성 항체 및 그의 용도
CN117279950B (zh) 一种靶向il-18bp的抗体及其应用
US20250333506A1 (en) Antibodies specific to delta 1 chain of t cell receptor
CN111423510B (zh) 重组抗人pd-1抗体及其应用
KR20250042144A (ko) Itga2를 표적으로 하는 항체 및 이를 포함하는 항체-약물 접합체(antibody targeting itga2 and antibody-drug conjugate comprising the same)
WO2020021061A1 (en) Humanized anti-pd-1 antibodies and uses thereof
CN119176876A (zh) 抗b7-h4抗体及其应用
US20250368742A1 (en) Anti-mica/b antibodies and uses thereof
CN118215680A (zh) 在治疗疾病中应用的多特异性抗体
WO2025131063A1 (en) Antibody drug conjugates targeting b7-h3 and trop2 and the use thereof
WO2024131835A1 (en) Ligand-cytotoxicity drug conjugates and pharmaceutical uses thereof
US20240368304A1 (en) Humanized f77 antibodies and fragments thereof
WO2025201493A1 (zh) Dll3结合分子及其用途
WO2025228377A1 (zh) B7-h3/egfr结合分子及其医药用途
WO2025190400A1 (zh) 抗dll3抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210315

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20220427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220428

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220719

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220922

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230815

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240215

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240216

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240528

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240627

R150 Certificate of patent or registration of utility model

Ref document number: 7513605

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150